THE INFLUENCE OF THERAPEUTIC MODALITIES ON THE FUNCTIONAL ABILITY OF PATIENTS WITH RHEUMATOID ARTHRITISon the functional ability of patients with rheumatoid arthritis
Abstract
Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disease. The progres-siveness of the disease and damage to the joints caused by RA can make a significant impact on the functioning ability. The gold standard for assessing functional status in RA is the HAQ questionnaire.
The aim of the study was to assess the impact of sociodemographic characteristics, laboratory parameters of interest and therapeutic modalities on the functional ability of patients with RA.
A retrospective cross-sectional study involved 109 patients, 29 male and 83 female, with a diagnosis of RA. Data on the demographic and clinical characteristics of the patients, laboratory findings and applied therapeutic modalities were collected. Microsoft Office Excel and PASW were used for statistical analysis. An estimation error level of less than 5% (0.05) was used as the statistical significance threshold.
The results of the study indicate that more than a third of the participants have a HAQ-DI greater than 1, which indicates a significant decrease in functional ability. The largest number of subjects with a high HAQ-DI index (41.2%) was observed in the group of subjects who used glucocorticoids in combination with several synthetic disease-modifying drugs (GC + multiDMARD). The values of HAQ-DI differ statistically significantly in relation to the applied therapeutic modalities (p = 0.004). HAQ-DI significantly correlated with the values of sedimentation rate (p < 0.05), CRP (p < 0.01) and anti-CCP (p < 0.05). PLUM regression analysis showed that functional ability was impaired in the group of subjects without and with a smaller number of comorbidities. In addition, the results of regression analysis indicate that the therapeutic modalities GC +methotrexate (p = 0.023) and GC + multiDMARD (p = 0.002) can significantly contribute to better functional ability in patients with RA.
Methotrexate, alone or in combination with other drugs, can significantly contribute to better functional ability and is effective in the treatment of most patients with RA.
References
Abud-Mendoza C, Martínez-Martínez MU. Triple ther-apy with non-biologic DMARDs for rheumatoid arthritis or biologic therapy. Is it the same? Reumatol Clin 2014;10(5):345-6. [CrossRef] [PubMed]
Ahlmén M, Svensson B, Albertsson K, Forslind K, Hafström I, BARFOT Study Group. Influence of gender on assessments of disease activity and function in early rheumatoid arthritis in relation to radiographic joint damage. Ann Rheum Dis 2010;69(1):230-3. [CrossRef] [PubMed]
Albrecht K, Zink A. Poor prognostic factors guiding treatment decisions in rheumatoid arthritis patients: a review of data from randomized clinical trials and cohort studies. Arthritis Research & Therapy 2017; 19:68. [CrossRef] [PubMed]
Bergstra S, Landewé R, Huizinga T, Allaart C. Rheumatoid arthritis patients with continued low disease activity have similar outcomes over 10 years, regardless of initial therapy. Rheumatology (Oxford). 2017;56(10):1721-8. [CrossRef] [PubMed]
Burmester GR, Pope JE. Novel treatment strategies in rheumatoid arthritis. Lancet. 2017;10;389(10086): 2338-48. [CrossRef] [PubMed]
Favalli EG, Biggioggero M, Meroni PL. Methotrexate for the treatment of rheumatoid arthritis in the biologic era: still an "anchor" drug? Autoimmun Rev 2014; 13(11):1102-1108. [CrossRef] [PubMed]
Gaujoux-Viala C, Nam J, Ramiro S, Landewé R, Buch MH, Smolen JS, Gossec L. Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 2014;73(3):510-5. [CrossRef] [PubMed]
Intriago M, Maldonado G, Cárdenas J, Ríos C. Clinical Characteristics in Patients with Rheumatoid Arthritis: Differences between Genders. ScientificWorldJournal 2019;2019:8103812. [CrossRef] [PubMed]
Ji J, Zhang L, Zhang Q, Yin R, Fu T, Li L, Gu Z. Functional disability associated with disease and quality-of-life parameters in Chinese patients with rheumatoid arthritis. Health Qual Life Outcomes 2017; 15(1):89. [CrossRef] [PubMed]
Jovanović J, Stojanović M, Jovanović V, Dimić A, Božilov S, Stamenković B, Milenković S. Influence of disease activity on functional capacity in patients with rheumatoid arthritis. Vojnosanit Pregl 2015;72(1):21-5. [CrossRef] [PubMed]
Kahlenberg JM, Fox DA. Advances in the Medical Treatment of Rheumatoid Arthritis. Hand Clin 2011; 27(1):11-20. [CrossRef] [PubMed]
Karpouzas GA, Draper T, Moran R, Hernandez E, Nicassio P, Weisman MH, Ormseth S. Trends in Functional Disability and Determinants of Clinically Meaningful Change Over Time in Hispanic Patients With Rheumatoid Arthritis in the US. Arthritis Care Res (Hoboken) 2017;69(2):294-8. [CrossRef] [PubMed]
Kopciuch D, Paczkowska A, Leszczynsk P, Michalak M, Nowakowskai E. Effect of therapy with anti-tnf α drugs and dmard on disease activity and health related quality of life among women with rheumatoid arthritis. Acta Pol Pharm 2016;73(2):547-54. [PubMed]
Martin WJ, Shim M, Paulus HE, Chaudhari S, Feng J, Elashoff D et al. Older age at rheumatoid arthritis onset and comorbidities correlate with less Health Assessment Questionnaire-Disability Index and Clinical Disease Activity Index response to etanercept in the RADIUS 2 registry. J Clin Rheumatol 2014;20(6): 301-5. [CrossRef] [PubMed]
Michaud K, Wallenstein G, Wolfe F. Treatment and nontreatment predictors of health assessment questionnaire disability progression in rheumatoid arthritis: a longitudinal study of 18,485 patients. Arthritis Care Res (Hoboken) 2011;63(3):366-72. [CrossRef] [PubMed]
Myasoedova E, Crowson CS, Kremers HM, Therneau TM, Gabriel SE. Is the incidence of rheumatoid arthritis rising?:results from Olmsted County, Minnesota, 1955-2007. Arthritis Rheum 2010;62:1576-82. [CrossRef] [PubMed]
National Collaborating Centre for Chronic Conditions. Rheumatoid Arthritis: National Clinical Guideline for Management and Treatment in Adults. London: Royal College of Physicians;2009. [PubMed]
Önder B, Kurtaran A, Kimyon S, Selçuk B, Akyüz M. Association of anti-CCP positivity with serum ferritin and DAS-28. Rheumatol Int 2009;30(2):223-7. [CrossRef] [PubMed]
Pincus T, Ferraccioli G, Sokka T, Larsen A, Rau R, Kushner I et al. Evidence from clinical trials and long-term observational studies that disease-modifying antirheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review. Rheumatology 2002;41:1346-56. [CrossRef] [PubMed]
Pollard L, Choy EH, Scott DL. The consequences of rheumatoid arthritis: quality of life measures in the individual patient. Clin Exp Rheumatol 2005;23(5 Suppl 39):S43-52. [PubMed]
Research USDoHaHSFCfDEa. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes 2006;4:79. [CrossRef] [PubMed]
Šenolt L, Grassi W, Szodoray P. Laboratory bio-markers or imaging in the diagnostics of rheumatoid arthritis? BMC Med 2014;12:49. [CrossRef] [PubMed]
Shams S, Martinez JM, Dawson JRD, Flores J, Gabriel M, Garcia G, et al. Therapeutic Landscape of Rheuma-toid Arthritis: Current State and Future Directions. Front Pharmacol 2021;12:680043. [CrossRef] [PubMed]
Shinde CG, Venkatesh MP, Kumar TM, Shivakumar HG. Methotrexate: a gold standard for treatment of rheumatoid arthritis. J Pain Palliat Care Pharmacother 2014;28(4):351-8. [CrossRef] [PubMed]
Smolen JS, Landewe R, Bijlsma J, Burmester GR, Dougados M, Kerschbaumer A et al. EULAR recom-mendations for the management of rheumatoid arthritis with synthetic and biological disease-modi-fying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017;76:960-77. [CrossRef] [PubMed]
Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M at al. EULAR recom-mendations for the management of rheumatoid arthritis with synthetic and biological disease-modi-fying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73(3):492-509. [CrossRef] [PubMed]
Suresh E, Lambert CM. Combination treatment stra-tegies in early rheumatoid arthritis. Ann Rheum Dis 2005;64(9):1252-6. [CrossRef] [PubMed]
Suresh E. Diagnosis of early rheumatoid arthritis: what the non-specialist needs to know. J R Soc Med 2004;97(9):421-24. [CrossRef] [PubMed]
Swierkot J, Szechiński J. Methotrexate in rheumatoid arthritis. Pharmacol Rep 2006;58(4):473-492.158.
Verstappen SMM, Jacobs JWG, Bijlsma JWJ, Heurkens AHM, Van BoomaFrankfort C, Ter Borg EJ et al. Five-year followup of rheumatoid arthritis patients after early treatment with disease-modifying antirheumatic drugs versus treatment according to the pyramid approach in the first year. Arthritis and Rheumatism 2003;48(7):1797-1807. [CrossRef] [PubMed]
Wisłowska M, Jakubicz D. Preliminary evaluation in rheumatoid arthritis activity in patients treated with TNF-alpha blocker plus methotrexate versus metho-trexate or leflunomide alone. Rheumatol Int 2007; 27(7):641-7. [CrossRef] [PubMed]